There was a lot of back slapping at this year's Australian Clinical Trial Seminar, held last week, that aimed to showcase Australia's capabilities and strengths in the clinical trial industry. The events, part of a collaboration project between the Korea Health Industry Development Institute and trade group AusBiotech, saw AusBiotech's COO Glenn Cross tell the Korea Times: "(South) Korea is one of AusBiotech's priority countries in the Asian region. I would like to see increased collaboration between Korean and Australian companies, especially in the regenerative medicine area through this visit." He added: "Australia welcomes more investment from Korean venture capital into Australia and active research and development and marketing activities by Korean companies." This comes just a week after Korean biotech startups were given a new boost after the government announced they would be helped with extra funding and advice. Report